Acrivon CAO granted 31,900 stock options

Acrivon Therapeutics, Inc. reported that its Chief Accounting Officer, Katharine Peterson, received a grant of stock options covering 31,900 shares of common stock.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported that its Chief Accounting Officer, Katharine Peterson, received a grant of stock options covering 31,900 shares of common stock. The options were awarded on March 1, 2026 at an exercise price of $0.00 per share as a form of equity compensation.

According to the vesting terms, 25% of the option shares vest on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments after that date. Vesting in all cases requires Ms. Peterson to remain in continuous service through each vesting date.

Insider Trade Summary

Grant/Award: 31,900 shares

Grant/Award 1 txn

Insider Peterson Katharine

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,900	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,900 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Katharine Peterson?

Acrivon Therapeutics reported a stock option grant to Chief Accounting Officer Katharine Peterson for 31,900 shares. The options were awarded on March 1, 2026 at an exercise price of $0.00 per share as part of her equity compensation package.

What is the size of the stock option grant to the ACRV Chief Accounting Officer?

The Chief Accounting Officer of Acrivon Therapeutics received a stock option grant for 31,900 shares. All 31,900 option shares were acquired in a single transaction on March 1, 2026 and reflect a new equity award reported on the Form 4 filing.

How do Katharine Peterson’s Acrivon stock options vest?

Katharine Peterson’s options vest over time, starting with 25% of the 31,900 shares on March 1, 2027. The remaining shares then vest in 36 substantially equal monthly installments, conditioned on her continuous service through each successive vesting date.

What was the exercise price of the ACRV stock options granted to the Chief Accounting Officer?

The stock options granted to Acrivon’s Chief Accounting Officer carry an exercise price of $0.00 per share. This means she does not pay a purchase price upon exercise, making the award a form of compensation tied to future vesting conditions.

Is the ACRV Form 4 transaction a purchase or a grant of stock options?

The ACRV Form 4 reflects a grant of stock options, not an open-market purchase. The transaction is coded as an acquisition (Code A) representing a grant or award of 31,900 options to the Chief Accounting Officer as part of her compensation package.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		31,900		(1)	02/29/2036	Common Stock	31,900	$0	31,900	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.